Search Results

Your search for Karen Kelly, MD matches 2 pages

Showing 1 - 2

By Karen Kelly, MD / 2015 IASLC World Conference on Lung Cancer

Karen Kelly, MD, on PD-1 Axis Inhibition and the Treatment of Advanced Disease

Karen Kelly, MD, of the University of California, Davis, summarizes three important papers on NSCLC: expression as a predictive biomarker; pembrolizumab, immune-mediated adverse events, and corticosteroid use; and an evaluation of disease-related symptoms in patients treated with nivolumab or...

lung cancer

issues in oncology

By Matthew Stenger / Tuesday, September 29, 2015 1:20 PM

Study Finds No Disease-Free Survival Improvement With Adjuvant Erlotinib in EGFR-Expressing NSCLC

In the phase III RADIANT trial reported in the Journal of Clinical Oncology, Kelly et al found no disease-free survival improvement with adjuvant erlotinib (Tarceva) vs placebo in patients with EGFR-expressing stage IB to IIIA non–small cell lung cancer (NSCLC). However, there was evidence of ...

Apr

Today In Oncology

Search Results

Your search for Karen Kelly, MD matches 2 pages

Karen Kelly, MD, on PD-1 Axis Inhibition and the Treatment of Advanced Disease

Study Finds No Disease-Free Survival Improvement With Adjuvant Erlotinib in EGFR-Expressing NSCLC

Induction and Concurrent Vismodegib With Radiation Therapy for Locally Advanced Unresectable Basal Cell Carcinoma

FDA Approves Nogapendekin Alfa Inbakicept-pmln for BCG-Unresponsive Non–Muscle Invasive Bladder Cancer

Predicting Ovarian Cancer Relapse With Spatial Tissue Analysis

Chemohormonal Therapy for Locally Advanced Prostate Cancer

Nivolumab With or Without Ipilimumab in Recurrent or Metastatic Cervical Cancer